Neuraxis (NRXS) Share-based Compensation (2022 - 2026)
Neuraxis (NRXS) posted Share-based Compensation of $399995.0 for Q1 2026, up 5403.51% sequentially from $7268.0 in Q4 2025, and up 255.57% YoY from $112493.0 in Q1 2025.
Neuraxis (NRXS) Share-based Compensation (2022 - 2026) Analysis & Trends
Neuraxis has reported Share-based Compensation for 3 years, with the latest figure at $399995.0 in Q1 2026.
- Quarterly Share-based Compensation rose 255.57% year-over-year to $399995.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $741170.0 (up 558.86% YoY) and the FY2025 annual result came in at $7268.0, changed N/A from the prior year.
- Share-based Compensation grew to $399995.0 in Q1 2026 per NRXS's latest filing, from $7268.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $399995.0 in Q1 2026 and troughed at $3198.0 in Q3 2022.
- A 3-year average of $142810.2 and a median of $136679.0 in 2025 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 255.57% in 2026, down 255.57% in 2026.
- Over 3 years, Share-based Compensation stood at $3198.0 in 2022, then jumped by 127.27% to $7268.0 in 2025, then soared by 5403.51% to $399995.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $399995.0, $7268.0, and $160865.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 399,995.00 |
| Mar 31, 2026 | 399,995.00 |
| Dec 31, 2025 | 7,268.00 |
| Dec 31, 2025 | 7,268.00 |
| Sep 30, 2025 | 160,865.00 |
| Sep 30, 2025 | 160,865.00 |
| Jun 30, 2025 | 173,042.00 |
| Jun 30, 2025 | 173,042.00 |
| Mar 31, 2025 | 112,493.00 |
| Mar 31, 2025 | 112,493.00 |
| Sep 30, 2022 | 3,198.00 |
| Sep 30, 2022 | 3,198.00 |